Active, not recruitingInterventional · Phase 2/3NCT02339571 ↗Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Active, not recruitingInterventional · Phase 2NCT03767348 ↗An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]Anna C PavlickPIInterventionBiological: RP1 · Biological: nivolumabDatesSep 2017 – Jun 2028 (est.)SponsorReplimune Inc.Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more
RecruitingInterventional · Phase 1/2NCT05361174 ↗A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerBarbara MaPIInterventionBiological: IOV-4001DatesJul 2022 – Sep 2027 (est.)SponsorIovance Biotherapeutics, IncUnresectable MelanomaMetastatic MelanomaStage III Non-small Cell Lung Cancer+1 more
RecruitingInterventional · Phase 1/2NCT05970497 ↗A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor MalignanciesAnna C PavlickPIInterventionBiological: KB707 · Drug: Opdualag · Drug: KEYTRUDA ®( Pembrolizumab)DatesOct 2023 – Jul 2027 (est.)SponsorKrystal Biotech, Inc.CancerMelanoma Stage IIIMelanoma Stage IV+1 more
RecruitingInterventional · Phase 1/2NCT06425926 ↗A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid TumorsAnna C PavlickPIInterventionDrug: GIM-531 · Drug: Anti-PD-1 monoclonal antibodyDatesMay 2024 – Dec 2026 (est.)SponsorGeorgiamune IncMelanoma Stage IVSolid Tumor
Active, not recruitingInterventional · Phase 3NCT06500455 ↗Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain MetastasesHani Lamie AshamallaPIInterventionProcedure: Computed Tomography · Radiation: Fractionated Stereotactic Radiation Therapy · Procedure: Magnetic Resonance Imaging · Radiation: Stereotactic RadiosurgeryDatesDec 2024 – Jun 2028 (est.)SponsorNRG OncologyAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Digestive System Carcinoma+7 more
RecruitingInterventional · Not applicableNCT07661966 ↗A Pilot Trial of Bright Light Therapy in Patients Receiving First Line Immune Checkpoint BlockadePaul ChapmanPIInterventionDevice: Bright Light TherapyDatesOct 2026 – Dec 2027 (est.)SponsorWeill Medical College of Cornell UniversityMelanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)
TerminatedInterventional · Phase 2NCT04032704 ↗Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid TumorsManish A ShahPIInterventionDrug: ladiratuzumab vedotin · Drug: pembrolizumabDatesOct 2019 – Nov 2023· Results postedSponsorSeattle Genetics, Inc.Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
CompletedInterventional · Phase 1/2NCT04208958 ↗Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerManish A ShahPIInterventionBiological: VE800 · Drug: Nivolumab · Drug: Vancomycin Oral CapsuleDatesJan 2020 – Aug 2021· Results postedSponsorVedanta Biosciences, Inc.Metastatic CancerMelanomaGastric Cancer+2 more
TerminatedInterventional · Phase 1NCT04254107 ↗A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced MalignanciesAnna C PavlickPIInterventionDrug: SEA-TGT · Drug: sasanlimab · Drug: brentuximab vedotinDatesMay 2020 – Dec 2023SponsorSeagen Inc.Non-small Cell Lung CancerGastric CarcinomaGastroesophageal Junction Carcinoma+9 more
CompletedInterventional · Phase 1NCT05293496 ↗A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid TumorsCora SternbergPIInterventionBiological: vobramitamab duocarmazine · Biological: lorigerlimabDatesApr 2022 – Jun 2025SponsorMacroGenicsAdvanced Solid TumorCastration-Resistant Prostatic CancerMalignant Melanoma+4 more
TerminatedInterventional · Phase 3NCT05665595 ↗A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)Anna C PavlickPIInterventionBiological: Pembrolizumab/Vibostolimab · Biological: PembrolizumabDatesJan 2023 – Mar 2024· Results postedSponsorMerck & Co., Inc.Melanoma
TerminatedInterventional · Phase 1NCT06034860 ↗A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesAnna C PavlickPIInterventionDrug: MT-8421 · Drug: NivolumabDatesNov 2023 – Oct 2024SponsorMolecular Templates, Inc.Non Small Cell Lung CancerHepatocellular CarcinomaMelanoma+8 more